Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

Stock Information for Mega Matrix Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mega Matrix Corp.

Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
Allena Pharmaceuticals Provides Clinical and Corporate Update
Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.